Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OSIRIX

Financiado

Cerrado

Revolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory...

Revolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections The best in class UNIVERSAL multi season influenza vaccine While an ongoing pandemic outbreak of coronavirus (COVID-19) is having enormous impact on global societies, a quest for effective vaccination becomes of unprecedented importance to save lives and economies globally. Symptomatic f... ver más

30/09/2022

OSIVAX

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

OSIVAX SAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

OSIVAX

2.46M€ | Lider

ROCKOLA MEDIA GROUP

634.77K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FLUNIVAC InFLUenza virus UNIVersal VACcine development program 7M€ Cerrado

ARCAS ARCAS Analysis of the Route to Commercialisation of MVA bas... 164K€ Cerrado

FLUTCORE Development of a universal influenza vaccine based on tandem... 4M€ Cerrado

DESARROLLO DE VACUNAS TERMOESTABLES BASADAS E... DESARROLLO DE VACUNAS TERMOESTABLES BASADAS EN MRNA FRENTE A... 2M€ Cerrado

RYC-2017-23255 Synthetic biology approaches to develop multivalent vaccines... 309K€ Cerrado

BES-2017-082074 EVOLUCION DEL VIRUS INFLUENZA PORCINA ASOCIADA A LA VACUNACI... 93K€ Cerrado

Duración del proyecto: 26 meses Fecha Inicio: 2020-07-16
Fecha Fin: 2022-09-30

Líder del proyecto

OSIVAX SAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto While an ongoing pandemic outbreak of coronavirus (COVID-19) is having enormous impact on global societies, a quest for effective vaccination becomes of unprecedented importance to save lives and economies globally. Symptomatic flu, another respiratory RNA viral infection, affects ~10% of global population every year and leads to regular pandemic outbreaks. Existing prophylactic vaccination requires updates each flu season or pandemic outbreak, and has a strikingly limited efficacy (40% on average, as low as 9% in elderly). This is mainly due to a rapid mutation rate of surface viral proteins that are targeted by the current vaccines. Governments, institutions and vaccine community urgently seek for a universal flu vaccine that would provide a multi-season protection against all seasonal and emerging pandemic viral strains. OSIVAX, a French clinical stage innovative biotech, strives to develop vaccines able to prevent respiratory viral infections across multiple seasons and outbreak. OSIVAX has developed OVX836, a best-in-class, game-changing universal flu vaccine candidate. OVX836 is based on oligoDOM®, a proprietary immune-boosting technology that triggers powerful, targeted and durable immune responses involving activation of specific immune response killing infected cells. OVX836 circumvents the need for annual vaccination updates by targeting an intraviral protein that is highly conserved across all influenza strains. OVX836 has a potential to disrupt the flu vaccine market currently dominated by single-season vaccines. The revolutionary universal flu vaccine is predicted to have a blockbuster potential (>€2.5 billion). OSIVAX’s experienced team aims to get OVX836 ready for the clinical proof-of-efficacy milestone (Phase IIb) that will position the company for >€500M licensing deal with a big pharma in 2024. At the moment, OSIVAX leverages this revolutionary clinical-stage technology to initiate the development of a universal vaccine against corona

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores